Vicki Keedy is an Oncology physician affiliated with Vanderbilt University. OpenAlex indexes 142 publications with 6,671 citations (h-index 32); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3601 The Vanderbilt Clinic
Nashville, TN 372320001
Telephone
615-936-2000Provider last certified this registry record 17 Dec 2025.
Clinical trials
- Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma
Sponsor: Vanderbilt-Ingram Cancer Center
- Everolimus and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastasis From Non-Small Cell Lung Cancer
Sponsor: Vanderbilt-Ingram Cancer Center
- Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
Sponsor: Merrimack Pharmaceuticals
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Deciphera Pharmaceuticals Inc.Program year20257 payments
- EMD Serono Research & Development Institute, Inc.Program year20251 payment
- Aadi Bioscience, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
65%Kinase inhibitor65%Imatinib Mesylate59%Votrient26%Pazopanib Hcl15%Part D<11 patientsSensory organs
14.8%Corticosteroid14.8%Dexamethasone100%Part D<11 patientsMetabolism & gastrointestinal
10.9%Serotonin-3 Receptor Antagonist10.9%Ondansetron Hcl100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2015–2021 per NIH RePORTER. The latest:
- Clinical Protocol and Data Management/Clinical Trials Office (Core-015)
Vanderbilt University Medical Center
FY2018$786,715P30CA068485
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Diagnosis and management of dedifferentiated liposarcoma: A multidisciplinary position statement
Cancer Treatment Reviews
2024 - Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2022
Similar KOLs
Other experts from the same institution or the same specialty.
James Crowe, MD
Vanderbilt University
Ingrid Mayer, MD
Vanderbilt University
Michael Debaun, MD
Vanderbilt University
Sam Chang, MD
Vanderbilt University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”